Sorafenib is a multi-kinase inhibitor which decreases cancer cells proliferation by targeting various seronine-treonine kinases, including members of the RAF family and receptor tyrosine kinases such as c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-β.102. This evidence concerns the gene FLT3 and cancer.